These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 12121834)
1. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Jaffrain-Rea ML; Di Stefano D; Minniti G; Esposito V; Bultrini A; Ferretti E; Santoro A; Faticanti Scucchi L; Gulino A; Cantore G Endocr Relat Cancer; 2002 Jun; 9(2):103-13. PubMed ID: 12121834 [TBL] [Abstract][Full Text] [Related]
2. Adrenocorticotropic hormone secreting pituitary adenomas: analysis of growth fraction using the MIB-1 antibody. Mastronardi L; Guiducci A; Spera C; Puzzilli F; Liberati F; Ruggeri A; Peciarolo A Tumori; 2000; 86(3):229-32. PubMed ID: 10939604 [TBL] [Abstract][Full Text] [Related]
3. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. Mastronardi L; Guiducci A; Puzzilli F BMC Cancer; 2001; 1():12. PubMed ID: 11570981 [TBL] [Abstract][Full Text] [Related]
4. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review. de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025 [TBL] [Abstract][Full Text] [Related]
11. Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients. Coli A; Asa SL; Fadda G; Scannone D; Chiloiro S; De Marinis L; Lauretti L; Ranelletti FO; Lauriola L Eur J Endocrinol; 2016 Mar; 174(3):307-14. PubMed ID: 26620390 [TBL] [Abstract][Full Text] [Related]
12. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. Losa M; Ciccarelli E; Mortini P; Barzaghi R; Gaia D; Faccani G; Papotti M; Mangili F; Terreni MR; Camanni F; Giovanelli M J Clin Endocrinol Metab; 2001 Nov; 86(11):5194-200. PubMed ID: 11701676 [TBL] [Abstract][Full Text] [Related]
13. [Significance of p53 protein expression and proliferative potential with MIB-1 on tumor recurrence of pituitary adenomas]. Miyagami M; Nakamura S No To Shinkei; 1998 Jan; 50(1):27-32. PubMed ID: 9493195 [TBL] [Abstract][Full Text] [Related]
14. Clinical features and growth fractions of pituitary adenomas. Yonezawa K; Tamaki N; Kokunai T Surg Neurol; 1997 Nov; 48(5):494-500. PubMed ID: 9352815 [TBL] [Abstract][Full Text] [Related]
16. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of RCAS1 in human pituitary adenomas. Umeoka K; Sanno N; Oyama K; Tahara S; Kurotani R; Ikuyama S; Nakashima M; Watanabe T; Osamura RY; Teramoto A Mod Pathol; 2001 Dec; 14(12):1232-6. PubMed ID: 11743045 [TBL] [Abstract][Full Text] [Related]
18. The clinical and pathological significance of nitric oxide synthase in human pituitary adenomas: a comparison with MIB-1. Onishi K; Kamida T; Momii Y; Abe T; Fujiki M Endocrine; 2014 May; 46(1):154-9. PubMed ID: 24008756 [TBL] [Abstract][Full Text] [Related]
20. Implications of the World Health Organization definition of atypia on surgically treated functional and non-functional pituitary adenomas. Sarkar S; Philip VJ; Cherukuri SK; Chacko AG; Chacko G Acta Neurochir (Wien); 2017 Nov; 159(11):2179-2186. PubMed ID: 28573325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]